Peripartum cardiomyopathy (PPCM) is a rare but potentially devastating form of cardiomyopathy occurring late in pregnancy or early postpartum period in previously healthy women. [@JR170062-1] Pregnancy associated heart failure was first described in the 1800s; however it was not until 1971 that Demakis and Rahimtoola who recognized the disease as a distinct entity and coined the term peripartum cardiomyopathy. [@JR170062-1] [@JR170062-2] [@JR170062-3] According to the 2010 European Society of Cardiology (ESC), diagnosis of PPCM is made by echocardiography demonstrating ejection fracture of \< 45% with or without the left ventricular dilation with no evidence of other potential etiologies of heart failure. [@JR170062-4] Our goal is to provide brief overview of PPCM, review published cases of PPCM treated with bromocriptine and outline pros and cons of the treatment strategy.

Incidence and Risk Factors
==========================

Incidence of PPCM in the United States varies widely from 1 in 1,000 to 1 in 4,000 live births. [@JR170062-5] The risk of PPCM is largely influenced by ethnicity with African-American women at highest risk followed by Asians, whites, and Hispanic women. [@JR170062-6] Geographically, the highest incidence is encountered in Haiti (1 in 300 pregnancies) and South Africa (1 in 1,000 pregnancies). [@JR170062-7] [@JR170062-8] [@JR170062-9] Other risk factors include multiparity, multifetal gestation, preeclampsia, gestational hypertension, and advanced maternal age. [@JR170062-8] In fact, greater than 50% of cases occur in women older than 30 years old. [@JR170062-1]

Treatment Options for PPCM
==========================

Treatment of PPCM is similar to other types of heart failure with reduced ejection fraction. Mainstay of therapy is salt and fluid restriction, diuretics, vasodilators, and beta blockers. Anticoagulation may be indicated in selected cases. However, the use of angiotensin converting enzyme inhibitors (ACE) and angiotensin receptor blockers, (ARB) which have been shown to reduce morbidity and mortality are deferred until after delivery. [@JR170062-7] [@JR170062-10] [@JR170062-11]

Natural History of PPCM and Outcomes
====================================

Overall, outcomes of PPCM tend to be favorable compared to other types of cardiomyopathies as it is less likely to progress to end stage than heart failure caused by other etiologies. [@JR170062-12] With current treatment modalities, PPCM patients have a 50% rate of recovery and 98% chance of survival. [@JR170062-13] Previously, it was thought that if PPCM were to resolve, it would do so within 6 months of diagnosis and it persisted past this time point; it was considered a poor prognostic factor. [@JR170062-2] However, more recently, Fett et al followed 116 Haitian patients with PPCM and only 27.6% achieved full recovery; of those who recovered, 53% did not achieve full recovery for at least 18 months. [@JR170062-14] While this may be specific to the Haitian population, it appears that this disease may take a more significant amount of time to resolve than previously thought. Further, the risk of recurrence of PPCM is high and those who have had a pregnancy complicated by it are counseled to avoid future pregnancy. [@JR170062-15]

Theories for Causation
======================

The exact etiology of PPCM remains unknown; however, significant advances have been made to elucidate causation of PPCM. The largest umbrella of hypotheses include the "oxidative stress--prolactin axis" and "antiangiogenic--signaling excess" hypotheses. [@JR170062-7] The "oxidative stress--prolactin axis" hypothesis stems from the elevated markers of inflammation and apoptosis found in PPCM. [@JR170062-16] [@JR170062-17] A transgenic mouse model of PPCM was developed to investigate potential mechanisms of the disease. Using this mouse model, Sliwa et al showed that oxidative stress allows expression and activation of a lysosomal enzyme, cathepsin D which cleaves serum prolactin into an antiangiogenic and pro apoptotic 16-kDa prolactin sub fragment that incite and propagates myocardial damage. [@JR170062-18] The study also showed that blocking the release of prolactin inhibited degeneration of the cardiac capillary network, thereby decreasing myocyte damage. [@JR170062-18] Another study by Forster at al showed that increased levels of both prolactin and interferongamma were associated with increased inflammatory status and adverse outcomes in PPCM. [@JR170062-19] Recent data show that the "oxidative stress--prolactin axis" and the "antiangiogenic--signaling excess" probably converges in a final pathway of imbalanced cardiac remodeling in the peripartum phase, thereby causing myocardial injury secondary to metabolic "shortages." [@JR170062-8] Other proposed causative factors which will not be described here, include: selenium deficiency, viral myocarditis, and immune mediated cardiac damage.

Bromocriptine as a Therapy for PPCM
===================================

Bromocriptine is an ergot derivative with dopamine agonistic activity that inhibits the release of prolactin from the anterior pituitary. It is FDA approved for the treatment of hyperprolactinemia-associated endocrine dysfunction, acromegaly, Parkinson\'s disease, and to improve glycemic control in type 2 diabetes mellitus. In the past, it has also been used to inhibit lactation when medically indicated. Given the evidence to support the oxidative stress--prolactin hypothesis of PPCM, bromocriptine has been introduced as a potential beneficial addition to standard the treatment for PPCM.

Since the publications of the oxidative stress--prolactin axis model, there has been significant interest in the use of bromocriptine for prolactin inhibition in PPCMP cases demonstrating a positive impact on left ventricular ejection fraction and NYHA (New York Heart Association) class. However, bromocriptine is not without risks. Serious adverse events have been reported in postpartum women using bromocriptine for lactation suppression including myocardial infarction, seizures, and stroke. [@JR170062-20] Among patients with adverse events after bromocriptine, many events may have been avoided if treatment was discontinued with the initial manifestations of adverse reaction. [@JR170062-21] While a causal relationship remains unclear, routine use of bromocriptine for prevention of physiologic lactation is not recommended. Cessation of lactation may also pose significant disadvantage to the neonate; however, Sliwa et al showed normal growth and survival of neonates with mothers treated with bromocriptine. [@JR170062-22] Bromocriptine is contraindicated in women with pregnancy-induced hypertension, as it can worsen blood pressures during pregnancy or postpartum periods. Therefore, the risk to benefit ratio of bromocriptine makes it a poor choice for lactation suppression but may be worth taking the risk of adverse events in PPCMP as it may significantly improve cardiac outcomes ( [Table 1](#TB170062-1){ref-type="table"} ).

###### Advantages and disadvantages of bromocriptine use in peripartum cardiomyopathy

  Advantages                                                             Disadvantages
  ---------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------
  FDA approved                                                           Lactation suppression
  Risk of serious adverse effects may be avoided with close monitoring   Worsening hypertension and may increase risk of neurologic events in those with pregnancy induced hypertension
  May improve NYHA functional class at follow up                         Reported risk of myocardial infarction
  May improve systolic and diastolic function                            Arterial thromboembolism

Abbreviation: FDA, Food and Drug Administration; NYHA, New York Heart Association.

Sources
-------

Authors manually searched PubMed/MedLine and ClinicalTrials.gov for English-language articles written from 2007 to 2018 using the search terms "bromocriptine and peripartum cardiomyopathy," "bromocriptine and cardiomyopathy."

Study Selection
===============

The Search strategy yielded 171 articles. After excluding duplicates, 86 studies were reviewed. Sixty-one articles involving the treatment of PPCMP were included, and of these, 17 were case reports of patients with PPCMP treated with bromocriptine; these studies were included in this review.

**Tabulation, Integration, and Results:** Seventeen of these articles were case reports of patients with peripartum cardiomyopathy treated with bromocriptine that were included.

Results
=======

We describe a review of the existing case studies from 2007 to 2018 that discusses use of bromocriptine in patients with PPCM ( [Table 2](#TB170062-2){ref-type="table"} and [3](#TB170062-3){ref-type="table"} ). These case reports describe the use of bromocriptine in 30 individual women, ranging in age from 18 to 43 years. The study subjects vary with respect to their country of origin, gravidities and parities, and gestational age. The onset of PPCM ranged from prior to delivery to as late as a month after delivery. The majority of these women recovered their left ventricular ejection fraction after receiving bromocriptine, typically dosed from 2.5 to 5 mg daily, in conjunction with the standard heart failure therapy. Though many women presented with low ejection fractions, (range: 8--45%), many were able to report NYHA classes II and I at time of follow-up.

###### Case reports of bromocriptine use in peripartum cardiomyopathy--descriptive data

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
       Author                                           Journal                                               Title                                                                                                                                      Maternal age   Mother\'s ethnicity   Gravidity and parity         GA     Onset (after delivery)      Delivery method
  ---- ------------------------------------------------ ----------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------ -------------- --------------------- ---------------------------- ------ --------------------------- ------------------------------------------------------------------------------------------
  1    Hilfiker-Kleiner et al 2007 [@JR170062-26]       Journal of the American College of Cardiology         Recovery from postpartum cardiomyopathy in 2 patients by blocking prolactin release with bromocriptine                                                                                                                                          

                                                                                                              Same as above                                                                                                                              32             NR                    NR                           NR     3 wk                        NR

                                                                                                              Same as above                                                                                                                              41             NR                    NR (twin gestation           NR     At delivery                 Elective\
                                                                                                                                                                                                                                                                                                                                                              **C** -section

  2    Habedank et al 2008 [@JR170062-27]               European Journal of Heart Failure                     Recovery from peripartum cardiomyopathy after treatment with bromocriptine                                                                 35             NR                    G1 (twin gestation)          36/6   3 d                         NSVD

  3    Jahns et al 2008 [@JR170062-28]                  American Journal of Obstetrics *&* Gynecology         Peripartum cardiomyopathy--a new treatment option by inhibition of prolactin secretion                                                     43             NR                    G1                           34/4   8 d                         **C** -section for maternal dyspnea

  4    Abe et al 2010 [@JR170062-29]                    Journal of Nippon Medical School                      Recovery from peripartum cardiomyopathy in a Japanese woman after administration of bromocriptine as a new treatment option                37             Japanese              G1                           33/0   Prior to delivery           Emergency **C** -section for nonreassuring fetal status and maternal acute heart failure

  5    Meyer et al 2010 [@JR170062-30]                  Journal of Medical Case Reports                       Bromocriptine treatment associated with recovery from peripartum cardiomyopathy in siblings: two case reports                                                                                                                                   

                                                                                                              Same as above                                                                                                                              35             African               G3P3                         NR     4 wk                        Elective **C** -section

                                                                                                              Same as above                                                                                                                              27             African               G2                           NR     "During second pregnancy"   **C** -section for imminent fetal asphyxia and amniotic infection syndrome

  6    Sliwa et al 2010 [@JR170062-22]                  Circulation                                           Evaluation of bromocriptine in the treatment of acute severe peripartum cardiomyopathy                                                                                                                                                          

                                                                                                              Same as above                                                                                                                              22             NR                    P2                           NR     8 d                         NR

                                                                                                              Same as above                                                                                                                              38             NR                    P3                           NR     14 d                        NR

                                                                                                              Same as above                                                                                                                              24             NR                    P1                           NR     26 d                        NR

                                                                                                              Same as above                                                                                                                              22             NR                    P2                           NR     7 d                         NR

                                                                                                              Same as above                                                                                                                              18             NR                    P2                           NR     24 d                        NR

                                                                                                              Same as above                                                                                                                              24             NR                    P2                           NR     7 d                         NR

                                                                                                              Same as above                                                                                                                              23             NR                    P1                           NR     4 d                         NR

                                                                                                              Same as above                                                                                                                              28             NR                    P1                           NR     30 d                        NR

                                                                                                              Same as above                                                                                                                              22             NR                    P1                           NR     2 d                         NR

                                                                                                              Same as above                                                                                                                              18             NR                    P1                           NR     3 d                         NR

  7    Emmert et al 2011 [@JR170062-31]                 The Annals of Thoracic Surgery                        Peripartum cardiomyopathy with cardiogenic shock: recovery after prolactin inhibition and mechanical support                               33             NR                    G2                           NR     3 d                         NR

  8    Ballo et al 2012 [@JR170062-32]                  Case Reports in Medicine                              Peripartum cardiomyopathy presenting with predominant left ventricular diastolic dysfunction: efficacy of bromocriptine                    37             White                 NR (twin gestation)          36     2 d                         NSVD

  9    Freerksen et al 2012 [@JR170062-33]              Hypertension in Pregnancy                             Massive respiratory dysfunction as sign of fulminant peripartum cardiomyopathy (PPCM)                                                      35             NR                    G3P2                         40/6   At delivery                 Emergency\
                                                                                                                                                                                                                                                                                                                                                              **C** -section for maternal respiratory dysfunction

  10   Hilfiker-Kleiner et al 2012 [@JR170062-34]       Current Heart Failure Reports                         16-kDa prolactin and bromocriptine in postpartum cardiomyopathy                                                                            41             NR                    NR (IVF twin gestation       NR     h                           **C** -section

  11   Schroeter et al 2012 [@JR170062-35]              Clinical Research in Cardiology                       Prothrombotic condition in a woman with peripartum cardiomyopathy treated with bromocriptine and an impella lp 2.5 heart pump              39             White                 G1                           NR     4 d                         NSVD

  12   Kotlica et al 2016 [@JR170062-36]                Clinical and Experimental Obstetrics and Gynecology   Peripartum cardiomyopathy: a case report of a patient with triplet pregnancy                                                               33             NR                    NR (IUI triplet gestation)   35/0   1 d                         **C** -section

  13   Hamdan et al 2017 [@JR170062-37]                 Journal of Critical Care                              Peripartum cardiomyopathy, place of drug therapy, assist devices, and outcomes after left ventricular assistance                                                                                                                                

                                                                                                              Same as above                                                                                                                              25             NR                    P1                           NR     17 d                        NR

                                                                                                              Same as above                                                                                                                              35             NR                    P3                           NR     1 mo                        NSVD

                                                                                                              Same as above                                                                                                                              38             NR                    P1                           NR     3 wk                        NR

  14   Horn et al 2017 [@JR170062-38]                   ESC Heart Failure                                     Complete recovery of fulminant peripartum cardiomyopathy on mechanical circulatory support combined with high-dose bromocriptine therapy   30             NR                    NR                           NR     4 mo                        NR

  15   Senanayake and Patabendige 2017 [@JR170062-39]   Journal of Medical Case Reports                       Two potentially lethal conditions of probable immune origin occurring in a pregnant woman: a case report                                   33             Lankan                P1                           38     2 wk                        **C** -section

  16   Kryczka et al 2018 [@JR170062-40]                American Journal of Case Reports                      Severe course of peripartum cardiomyopathy and subsequent recovery in a patient with a novel ttn gene-truncating mutation                  25             White                 P1                           36     N/A                         **C** -section

  17   Huang et al 2018 [@JR170062-41]                  Medicine                                              Successful management of fatal peripartum cardiomyopathy in a young pregnant woman: a case report                                          18             NR                    P1                           33     N/A                         **C** -section
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: ESC, European Society of Cardiology; GA, gestational age; IUI, intrauterine insemination; IVF, in vitro fertilization; N/A, not applicable; NR, not reported; NSVD, normal spontaneous vaginal delivery; PPCM, peripartum cardiomyopathy.

###### Case reports of bromocriptine use in peripartum cardiomyopathy--treatment and outcome data

       Author                                           LVEDd at diagnosis (mm)   LVEF at diagnosis (%)   NYHA class at diagnosis   Treatment (other than bromocriptine)                                                                                                  Bromocriptine dosing                                                                                                   LVEDd after treatment (mm)       LVEF after treatment                              NYHA class after treatment
  ---- ------------------------------------------------ ------------------------- ----------------------- ------------------------- ------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------- -------------------------------- ------------------------------------------------- ---------------------------------
  1    Hilfiker-Kleiner et al 2007 [@JR170062-26]                                                                                                                                                                                                                                                                                                                                                                                                                                   
                                                        60                        17                      III                       Standard heart failure therapy                                                                                                        Bromocriptine 5 mg/d for 2 wk, then 2.5 mg/d for 6 wk                                                                  59 at 2 wk; 51 at 4, 6 mo        29% at 2 wk, 57% at 4 mo, 60% at 6 mo             I at 12 mo
                                                        55                        30                      IV                        Standard heart failure therapy                                                                                                        Bromocriptine, unspecified                                                                                             53 at 2 wk; 43 at 4 mo           50% at 2 wk, 49% at 4 mo                          I at 4 mo
  2    Habedank et al 2008 [@JR170062-27]               60                        25                      NR                        Torasemide 5 mg, ramipril 2.5 mg, spironolactone 25 mg, bisoprolol 2.5 mg.                                                            After 3 d of continued deterioration, started treatment with Bromocriptine 2.5 mg twice daily and continued for 6 wk   56 at 2 mo                       60% at 2 mo                                       I at 2 mo
  3    Jahns et al 2008 [@JR170062-28]                  NR                        30                      NR                        Angiotensin-converting enzyme inhibitor, digoxin, beta blocker                                                                        Bromocriptine 2.5 mg/d for at least 3 mo                                                                               NR                               43% at discharge; 50% at 6 mo                     NR
  4    Abe et al 2010 [@JR170062-29]                    58                        21.70                   II                        Dobutamine, furosemide; starting at 11 d given losartan 25 mg; bisoprolol 2.5 mg                                                      Bromocriptine 5 mg/d beginning 11 d after diagnosis, continued for 12 wk                                               51 at 3 mo                       60% at 3 mo                                       I at 3 mo
  5    Meyer et al 2010                                                                                                                                                                                                                                                                                                                                                                                                                                                             
                                                        63                        9                       IV                        Enoxaparin, Coumadin, and standard heart failure therapy                                                                              Bromocriptine 5 mg/d for 2 wk, 2.5 mg/d for 6 wk                                                                       NR                               45% at 6 mo                                       II at 6 mo
                                                        60                        32                      NR                        Enoxaparin, standard heart failure therapy                                                                                            Bromocriptine 5 mg/d for 2 wk, 2.5 mg/d for 6 wk                                                                       NR                               59% at 8 mo                                       NR
  6    Sliwa et al 2010 [@JR170062-22]                                                                                                                                                                                                                                                                                                                                                                                                                                              
                                                        33                        34                      IV                        Carvedilol, enalapril, furosemide, aldactone                                                                                          Bromocriptine 2.5 twice daily for 2 wk followed by 2.5 mg/d for 6 wk                                                   44                               58%                                               I at 6 mo
                                                        65                        29                      II                        Carvedilol, enalapril, furosemide, aldactone                                                                                          Same as above                                                                                                          59                               37%                                               I at 6 mo
                                                        68                        30                      II                        Carvedilol, enalapril, furosemide, aldactone                                                                                          Same as above                                                                                                          65                               62%                                               I at 6 mo
                                                        54                        27                      II                        Carvedilol, enalapril, furosemide, aldactone                                                                                          Same as above                                                                                                          51                               72%                                               I at 6 mo
                                                        56                        30                      II                        Carvedilol, enalapril, furosemide, aldactone                                                                                          Same as above                                                                                                          48                               56%                                               I at 6 mo
                                                        63                        30                      III                       Carvedilol, enalapril, furosemide, aldactone                                                                                          Same as above                                                                                                          51                               58%                                               I at 6 mo
                                                        55                        33                      IV                        Carvedilol, enalapril, furosemide, aldactone                                                                                          Same as above                                                                                                          47                               60%                                               I at 6 mo
                                                        49                        32                      II                        Carvedilol, enalapril, furosemide, aldactone                                                                                          Same as above                                                                                                          34                               75%                                               I at 6 mo
                                                        55                        18                      III                       Carvedilol, enalapril, furosemide, aldactone                                                                                          Patient died on index admission                                                                                        N/A                              N/A                                               Patient died on index admission
                                                        54                        8                       III                       Carvedilol, enalapril, furosemide                                                                                                     Bromocriptine 2.5 twice daily for 2 wk followed by 2.5 mg/d for 6 wk                                                   56                               48%                                               I at 6 mo
  7    Emmert et al 2011 [@JR170062-31]                 77                        23                      NR                        Cabergoline 1 mg, acute heart failure treatment, intra-aortic balloon pump, left ventricular assist device,                           Bromocriptine 2.5 mg/d for 6 wk                                                                                        50 at 14 mo after LVAD removal   After surgery 42%; 14 mo after LVAD removal 47%   I at 14 mo after LVAD removal
  8    Ballo et al 2012 [@JR170062-32]                  NR                        35                      II                        Ramipril, bisoprolol, furosemide                                                                                                      Bromocriptine 2.5 mg twice daily 2 wk after diagnosis                                                                  NR                               45% at 6 wk; 60% at 18 mo                         I at 6 wk and 18 mo
  9    Freerksen et al 2012 [@JR170062-33]              NR                        15                      IV                        Levosimendan; required left ventricular assist device on d 7 postpartum                                                               Bromocriptine 2.5 mg/d at d 1; 1.5 mg/d from d 2 onwards                                                               NR                               Stabilized but LVEF NR                            NR
  10   Hilfiker-Kleiner et al 2012 [@JR170062-34]       NR                        26                      IV                        Bisoprolol, enlapril, spironolactone, torsemide, phenprocoumon                                                                        Bromocriptine 5 mg/d                                                                                                   NR                               62% at 6 mo                                       NR
  11   Schroeter et al 2012 [@JR170062-35]              59                        45                      NR                        Levosimendan 8ug/min, Impella LP 2.5 percutaneous micro-axial pump assist device                                                      Bromocriptine 2.5 mg twice daily                                                                                       49 at discharge on d 21          NR                                                NR
  12   Kotlica et al 2016 [@JR170062-36]                55                        25--30                  NR                        Dobutamine, furosemide, manitol, low molecular weight heparin, magnesium sulfate, ACE inhibitors, xylocaine, digitalis, antibiotics   Bromocriptine, dose NR                                                                                                 "Normal dimension"               64% at d 18                                       NR
  13   Hamdan et al 2017 [@JR170062-37]                                                                                                                                                                                                                                                                                                                                                                                                                                             
                                                        NR                        15--20                  NR                        ECMO, inotropes, diurectics, HVAD                                                                                                     Bromocriptine 2.5 mg/d for 3 d                                                                                         NR                               45% at 6 mo                                       NR
                                                        NR                        30                      NR                        Beta blockers, ACE inhibitor, aldosterone agonist, diurectics                                                                         Bromocriptine 2.5 mg/d for 7 d                                                                                         NR                               35% at 10 d; 60% at 2 y                           I at 2 y
                                                        NR                        25                      III                       Diurectics, "conventional (heart failure) treatment"                                                                                  Bromocriptine 2.5mg/d for 10 d                                                                                         NR                               40% within "d;" 55% at 9 mo                       NR
  14   Horn et al 2017 [@JR170062-38]                   NR                        NR                      NR                        ECMO, "optimal medical heart failure therapy"                                                                                         Bromocriptine 5 mg/d via gavage; increased to 10 mg daily for 8 wk                                                     NR                               "Normal" at 3 mo                                  I at 1 y
  15   Senanayake and Patabendige 2017 [@JR170062-39]                             45                      NR                        Warfarin, "heart failure regimen"                                                                                                     Bromocriptine, unspecified                                                                                             NR                               60% at 6 wk postpartum                            NR
  16   Kryczka et al 2018 [@JR170062-40]                NR                        25--0                   NR                        NR                                                                                                                                    Bromocriptine, unspecified for 12 mo                                                                                   NR                               32% at 10 wk                                      NR
  17   Huang et al 2018 [@JR170062-41]                  NR                        40                      NR                        Digoxin, furosemide, losartan                                                                                                         Bromocriptine 5 mg/d for 3 mo                                                                                          NR                               51% at 3 mo; 62% at 6 mo                          NR

Abbreviation: ACE, angiotensin converting enzyme; ECMO, extracorporeal membrane oxygenation; HVAD, HeartWare ^®^ ventricular assist device; LVAD, left ventricular assist device; LVEDd, left ventricular end diastolic diameter; LVEF, left ventricular ejection fraction; NR, not report; NYHA, New York Heart Association.

While most of these are individual, heterogeneous case reports, 10 of these cases came from a pilot study comparing women with newly diagnosed PPCM receiving standard heart failure care ( *n*  = 10) versus standard care and bromocriptine ( *n*  = 10). This study demonstrated that the addition of bromocriptine to standard heart failure therapy improved NYHA functional class, left ventricular systolic and diastolic function, and degree of functional mitral regurgitation in women with PPCMP. Though this trial was small and far from definitive, the data appeared to show greater improvement in the group that received bromocriptine. Subsequently, a multicenter randomized controlled trial evaluated outcomes of 63 patients with PPCM who were treated with 1 or 8 weeks of bromocriptine in addition to standard therapy revealed that patients treated with bromocriptine was associated with higher rate of left ventricular recovery and had low morbidity and mortality. [@JR170062-23] Post hoc analysis of this study demonstrated an improvement of the right ventricular function in addition to the left ventricular function at 6 month follow-up in women treated with bromocriptine. [@OR170062-24] Bromocriptine may have a role in PPCMP patients with biventricular dysfunction. Addition of bromocriptine to the standard heart failure therapy, i.e. BOARD (Bromocriptine, Oral heart failure drugs, Anticoagulation, Relaxants \[vasodilators for SBP \> 110 mm Hg\], Diuretics) has been proposed. Of note, prophylactic anticoagulation should be used when using bromocriptine to reduce the risk of thromboembolic complications. [@JR170062-25]

Conclusion
==========

There is currently insufficient evidence for universal use of bromocriptine in addition to the standard treatment of PPCM. However, there are data to suggest that bromocriptine improves clinical outcomes. We recommend consideration of bromocriptine in selected cases of PPCMP. Future studies are indicated to elucidate its role as a standard therapy.

Bromocriptine seems to be a promising treatment for peripartum cardiomyopathy but there is a need for further clinical trials.
